PolarityBio Secures AMA CPT Codes for Autologous Skin Construct Therapy, Advancing Wound Healing Treatment Access
核心洞察
The American Medical Association CPT Editorial Panel has accepted PolarityBio (搜索)'s Category III CPT Code Application for its autologous heterogeneous skin construct graft therapy.
The acceptance establishes dedicated CPT codes X505T–X510T, creating a standardized reporting mechanism for providers using PolarityBio (搜索)'s regenerative skin therapy.
The new codes will be released January 1, 2026, and become effective for clinical use in July 2026, supporting future reimbursement pathways.
PolarityBio (搜索), a clinical-stage biotechnology company specializing in autologous regenerative skin multicellular therapy, has achieved a significant regulatory milestone with the American Medical Association (AMA) CPT Editorial Panel's acceptance of its Category III CPT Code Application for autologous heterogeneous skin construct grafts.
The acceptance establishes Category III CPT codes X505T–X510T, creating a dedicated mechanism for healthcare providers to report autologous heterogeneous skin construct graft procedures in clinical use of PolarityBio (搜索)'s autologous skin multicellular therapy.
Regulatory Infrastructure Development
"The AMA's acceptance of these Category III CPT codes marks a consequential milestone in establishing the necessary infrastructure for broader clinical adoption of autologous heterogeneous skin construct grafts," said John Stetson, Chief Executive Officer of PolarityBio (搜索). "This decision helps establish the infrastructure needed for data collection and reporting that will support future reimbursement pathways and expanded patient access to this innovative regenerative therapy."
The new codes are scheduled for release on January 1, 2026, and will become effective for clinical use in July 2026. Category III CPT codes serve as temporary designations for emerging technologies, services, and procedures, enabling critical data tracking to document clinical utility and value—essential steps toward achieving broader reimbursement and adoption.
SkinTE Development Program
PolarityBio (搜索)'s lead regenerative biologic, SkinTE, represents an autologous skin multicellular therapy currently under investigation. The company maintains an open investigational new drug application (IND) with the U.S. Food and Drug Administration (搜索) (FDA) and is pursuing the final pivotal study needed to support a biologics license application (BLA) for a Wagner 1 diabetic foot ulcer (搜索) indication.
The Salt Lake City-based biotechnology company focuses on addressing unmet needs in wound healing (搜索) through innovation in autologous regenerative skin multicellular therapy. SkinTE remains available for investigational use only as the company advances through its clinical development program.
Clinical and Commercial Implications
The acceptance of dedicated CPT codes represents a critical step in the commercialization pathway for regenerative wound healing (搜索) therapies. By establishing standardized reporting mechanisms, the codes facilitate systematic data collection on clinical outcomes and utilization patterns, information essential for demonstrating value to payers and supporting reimbursement decisions.
The temporary nature of Category III codes allows for comprehensive evaluation of emerging technologies while providing a framework for clinical adoption and data generation. This regulatory recognition positions PolarityBio (搜索)'s autologous skin construct technology for potential broader clinical implementation pending successful completion of pivotal studies and regulatory approval.